Access
To read this story in full you will need to login or make a payment (see right).
Article
Nature 453, 1072-1078 (19 June 2008) | doi:10.1038/nature07016; Received 14 December 2007; Accepted 22 April 2008; Published online 11 May 2008
Open Innovation Challenges
-
Single-cell Analysis Platform
This Challenge is looking for novel approaches to analyzing changes at a single-cell level. This is...
-
Novel Approaches to Protecting Maize from Insect Damage
The Seeker is looking for novel approaches to protecting maize from insect damage. This Challenge re...
nature jobs
Research Scientist – Ecology of Phytoplankton and Primary Producers (Experimental Lakes Area)
- Fisheries and Oceans Canada (DFO)
- Winnipeg, Manitoba, Canada
Postdoctoral Research Associate
- Rice University
- Houston, Texas, USA
PML targeting eradicates quiescent leukaemia-initiating cells
Keisuke Ito1,3,4, Rosa Bernardi1,3,4, Alessandro Morotti1,3,4, Sahoko Matsuoka5, Giuseppe Saglio6, Yasuo Ikeda5, Jacalyn Rosenblatt2, David E. Avigan2, Julie Teruya-Feldstein4 & Pier Paolo Pandolfi1,3,4
- Cancer Genetics Program, Beth Israel Deaconess Cancer Center, Departments of Medicine and Pathology,
- Division of Hematology and Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, New Research Building, 330 Brookline Avenue, Boston, Massachusetts 02215, USA
- Cancer Biology and Genetics Program,
- Department of Pathology, Memorial Sloan-Kettering Cancer Center, Sloan-Kettering Institute, 1275 York Avenue, New York, New York 10021, USA
- Division of Hematology, Department of Internal Medicine, Keio University School of Medicine, 35 Shinano-machi, Shinjuku-ku, Tokyo 160-8582, Japan
- Division of Hematology and Internal Medicine, Department of Clinical and Biological Sciences, University of Turin, Turin 10043, Italy
Correspondence to: Pier Paolo Pandolfi1,3,4 Correspondence and requests for materials should be addressed to P.P.P. (Email: ppandolf@bidmc.harvard.edu).
Abstract
The existence of a small population of 'cancer-initiating cells' responsible for tumour maintenance has been firmly demonstrated in leukaemia. This concept is currently being tested in solid tumours. Leukaemia-initiating cells, particularly those that are in a quiescent state, are thought to be resistant to chemotherapy and targeted therapies, resulting in disease relapse. Chronic myeloid leukaemia is a paradigmatic haematopoietic stem cell disease in which the leukaemia-initiating-cell pool is not eradicated by current therapy, leading to disease relapse on drug discontinuation. Here we define the critical role of the promyelocytic leukaemia protein (PML) tumour suppressor in haematopoietic stem cell maintenance, and present a new therapeutic approach for targeting quiescent leukaemia-initiating cells and possibly cancer-initiating cells by pharmacological inhibition of PML.
To read this story in full you will need to login or make a payment (see right).
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
RESEARCH
Evidence that bone morphogenetic protein 4 has multiple biological functions during kidney and urinary tract developmentKidney International Original Article
See all 30 matches for Research
